• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.成人非中性粒细胞减少患者念珠菌血症的治疗——一个尴尬的事实。
Crit Care. 2011;15(1):114. doi: 10.1186/cc9414. Epub 2011 Jan 31.
2
Initial antifungal strategy does not correlate with mortality in patients with candidemia.初始抗真菌策略与念珠菌血症患者的死亡率无关。
Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):187-93. doi: 10.1007/s10096-015-2527-2. Epub 2015 Dec 3.
3
Candidemia in children.儿童念珠菌血症。
Curr Med Res Opin. 2010 Jul;26(7):1761-8. doi: 10.1185/03007995.2010.487796.
4
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
5
[Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].[非中性粒细胞减少患者念珠菌血症的当前治疗。两性霉素B还是氟康唑?对62例连续患者的回顾性研究]
Rev Clin Esp. 1997 Dec;197(12):799-803.
6
Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.氟康唑或棘白菌素是念珠菌血症的首选药物吗?
Ann Pharmacother. 2015 Sep;49(9):1068-74. doi: 10.1177/1060028015590838. Epub 2015 Jun 23.
7
Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?氟康唑敏感的剂量依赖性光滑念珠菌血症癌症患者的初始治疗:与唑类药物相比,棘白菌素或多烯类药物是否有更好的结局?
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00631-17. Print 2017 Aug.
8
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.氟康唑与两性霉素B作为经验性抗真菌药物用于长期发热和中性粒细胞减少癌症患者的随机对照研究。
Am J Med. 1998 Dec;105(6):478-83. doi: 10.1016/s0002-9343(98)00326-x.
9
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.阿尼芬净与氟康唑治疗严重侵袭性念珠菌病(包括念珠菌血症)患者的比较:支持 2009IDSA 念珠菌病治疗指南。
Crit Care. 2011;15(5):R253. doi: 10.1186/cc10514. Epub 2011 Oct 25.
10
Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018.9 个主动监测点成人念珠菌血症治疗实践-美国,2017-2018 年。
Clin Infect Dis. 2021 Nov 2;73(9):1609-1616. doi: 10.1093/cid/ciab512.

引用本文的文献

1
Invasive fungal infections in the ICU: how to approach, how to treat.重症监护病房中的侵袭性真菌感染:如何诊治。
Molecules. 2014 Jan 17;19(1):1085-119. doi: 10.3390/molecules19011085.
2
Treatment of invasive candidiasis in the elderly: a review.老年侵袭性念珠菌病的治疗:综述。
Clin Interv Aging. 2013;8:1199-208. doi: 10.2147/CIA.S39120. Epub 2013 Sep 9.
3
Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?棘白菌素类——侵袭性念珠菌病的一线治疗药物:这种“有力”证据有多强?
Crit Care. 2011;15(6):461; author reply 461. doi: 10.1186/cc10580. Epub 2011 Dec 15.

本文引用的文献

1
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.侵袭性念珠菌感染的抗真菌治疗:一项混合治疗比较的荟萃分析。
Ann Clin Microbiol Antimicrob. 2009 Jun 26;8:23. doi: 10.1186/1476-0711-8-23.
2
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.念珠菌病管理临床实践指南:美国传染病学会2009年更新版
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
3
Treatment of invasive candidal infections: systematic review and meta-analysis.侵袭性念珠菌感染的治疗:系统评价与荟萃分析
Mayo Clin Proc. 2008 Sep;83(9):1011-21. doi: 10.4065/83.9.1011.
4
Echinocandins--first-choice or first-line therapy for invasive candidiasis?棘白菌素类药物——侵袭性念珠菌病的首选治疗还是一线治疗?
N Engl J Med. 2007 Jun 14;356(24):2525-6. doi: 10.1056/NEJMe078078.
5
Anidulafungin versus fluconazole for invasive candidiasis.阿尼芬净与氟康唑治疗侵袭性念珠菌病的比较
N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906.
6
Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.理解非劣效性:从临床和统计学角度看其在心血管临床试验中的应用
Prog Cardiovasc Dis. 2007 Jan-Feb;49(4):284-99. doi: 10.1016/j.pcad.2006.10.001.
7
Echinocandins for candidemia in adults without neutropenia.棘白菌素类药物用于非中性粒细胞减少的成人念珠菌血症治疗
N Engl J Med. 2006 Sep 14;355(11):1154-9. doi: 10.1056/NEJMct060052.
8
Lessons from and cautions about noninferiority and equivalence randomized trials.非劣效性和等效性随机试验的经验教训与注意事项。
JAMA. 2006 Mar 8;295(10):1172-4. doi: 10.1001/jama.295.10.1172.
9
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.两性霉素B、卡泊芬净、氟康唑和伏立康唑对血液系统恶性肿瘤患者罕见念珠菌属血流分离株的体外药效学特征
Antimicrob Agents Chemother. 2004 Nov;48(11):4453-6. doi: 10.1128/AAC.48.11.4453-4456.2004.
10
Patterns of amphotericin B killing kinetics against seven Candida species.两性霉素B对七种念珠菌的杀菌动力学模式。
Antimicrob Agents Chemother. 2004 Jul;48(7):2477-82. doi: 10.1128/AAC.48.7.2477-2482.2004.

成人非中性粒细胞减少患者念珠菌血症的治疗——一个尴尬的事实。

Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.

机构信息

Unidade de Cuidados Intensivos Polivalente, Hospital São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, EPE, Estrada do Forte do Alto do Duque, 1449-005 Lisboa, Portugal.

出版信息

Crit Care. 2011;15(1):114. doi: 10.1186/cc9414. Epub 2011 Jan 31.

DOI:10.1186/cc9414
PMID:21345263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3222043/
Abstract

In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.

摘要

2009 年,美国传染病学会审查了关于非中性粒细胞减少患者念珠菌血症治疗的指南。在本文件中,首选治疗方法是氟康唑或棘白菌素类药物。两性霉素 B 制剂被认为是一种替代药物。然而,对已发表数据的仔细评估表明,这些药物的疗效相似。